Kotaro Matsumoto*†, Katsuya Suzuki, Masaru Takeshita, Tsutomu Takeuchi and Yuko Kaneko Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan Giant cell arteritis and Takayasu arteritis are two types of primary large-vessel vasculitis (LVV). Although glucocorticoids (GC) are the standard treatment for LVV, the disease relapse rates are high.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Chie Miyabe
Chemokines in rheumatic diseases: pathogenic role and therapeutic implications
Abstract Chemokines, a family of small secreted chemotactic cytokines, and their G protein-coupled seven transmembrane spanning receptors control the migratory patterns, positioning and cellular interactions of immune cells. The levels of chemokines and their receptors are increased in the blood and within inflamed tissue of patients with rheumatic diseases, such as rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, vasculitis or idiopathic inflammatory myopathies.
Abrogation of lysophosphatidic acid receptor 1 ameliorates murine vasculitis
Research article Open Access Published: 20 August 2019 Chie Miyabe1,2, Yoshishige Miyabe1, Jun Nagai3, Noriko N.
Atypical complement receptor C5aR2 transports C5a to initiate neutrophil adhesion and inflammation
Atypical attraction Neutrophils contribute to inflammatory responses by moving from the circulation into target tissues through a series of chemoattractant-driven steps involving arrest and transmigration. Here, Miyabe et al.
An expanded population of pathogenic regulatory T cells in giant cell arteritis is abrogated by IL-6 blockade therapy
Objectives Randomised-controlled trials have recently proven the efficacy of the interleukin (IL)-6 receptor antagonist tocilizumab (TCZ) in giant cell arteritis (GCA). However, the mechanism of action of IL-6 blockade in this disease is unknown. Moreover, the role of regulatory T (Treg) cells in the pathogenesis of GCA remains underexplored. Given the plasticity of Tregs and the importance of IL-6 in their biology, we hypothesised that TCZ might modulate the Treg response in GCA.
An expanded population of pathogenic regulatory T cells in giant cell arteritis is abrogated by IL-6 blockade therapy
Objectives Randomised-controlled trials have recently proven the efficacy of the interleukin (IL)-6 receptor antagonist tocilizumab (TCZ) in giant cell arteritis (GCA). However, the mechanism of action of IL-6 blockade in this disease is unknown. Moreover, the role of regulatory T (Treg) cells in the pathogenesis of GCA remains underexplored. Given the plasticity of Tregs and the importance of IL-6 in their biology, we hypothesised that TCZ might modulate the Treg response in GCA.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Chie
Contact Chie, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack